the effect of Nebulized Hypertonic3% Saline in the Treatment of Acute bronchiolitis in pediatric ward

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012110510222N2

Enrollment

Registered

2013-01-28

Start date

2013-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

brochiolitis. Acute bronchiolitis due to respiratory syncytial virus

Interventions

Intervention 1: Intervention group: 2 weeks,get hypersalin 3%. Intervention 2: Control group:2weeks,get ventolin.

Treatment - Drugs

Intervention group: 2 weeks,get hypersalin 3%.

Control group:2weeks,get ventolin

Eligibility

Sex/Gender

All

Age

No minimum to 2 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: diagnosis of bronchiolitis, admission in Pediatric ward, Exclusion criteria:any underlying disease (e.g., cystic fibrosis, bronchopulmonary dysplasia and cardiac or renal disease, wheezing, atopic dermatitis, allergic rhinitis or asthma, oxygen saturation (SaO2) <85% on room air, progressive respiratory failure requiring mechanical ventilation, previous treatment with bronchodilators, and any steroid therapy within 2 weeks.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Bronchiolitis symptom. Timepoint: at base line, two weeks later. Method of measurement: examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Keivani

Shahrekord University Of Medical Sciences

keivaniz@yahoo.com+98 38 1222 0016

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026